» Articles » PMID: 20832512

Bisphosphonates in Paget's Disease

Overview
Journal Bone
Date 2010 Sep 14
PMID 20832512
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Paget's disease is the best example of a common high turnover bone disease. A review of the early use of bisphosphonates in the treatment of this condition shows that many of the fundamental therapeutic issues were identified using drugs which by today's standards were far from ideal. Over the succeeding decades there has been a steady increase in potency culminating in the introduction of intravenous zoledronic acid which is capable of inducing long term remissions which were unthinkable when bisphosphonates were first introduced.

Citing Articles

A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases.

Okagu I, Ezeorba T, Aguchem R, Ohanenye I, Aham E, Okafor S Int J Mol Sci. 2022; 23(15).

PMID: 35955603 PMC: 9368769. DOI: 10.3390/ijms23158468.


Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview.

Desai S, Manjappa A, Khulbe P J Egypt Natl Canc Inst. 2021; 33(1):4.

PMID: 33555490 DOI: 10.1186/s43046-021-00059-3.


Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.

Liel Y, Tailakh M Endocrine. 2018; 63(3):651-656.

PMID: 30406885 DOI: 10.1007/s12020-018-1806-y.


Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62 mouse model of Paget's disease.

Daroszewska A, Rose L, Sarsam N, Charlesworth G, Prior A, Rose K Dis Model Mech. 2018; 11(9).

PMID: 30154079 PMC: 6177010. DOI: 10.1242/dmm.035576.


Engineering of a New Bisphosphonate Monomer and Nanoparticles of Narrow Size Distribution for Antibacterial Applications.

Tal N, Rudnick-Glick S, Grinberg I, Natan M, Banin E, Margel S ACS Omega. 2018; 3(2):1458-1469.

PMID: 30023805 PMC: 6044825. DOI: 10.1021/acsomega.7b01686.